Global Induced Pluripotent Stem Cells Production Market to reach USD 1.60 billion by 2027.Global Induced Pluripotent Stem Cells Production Market is valued approximately USD 0.5 billion in 2020 and is anticipated to grow with a healthy growth rate of more than 8.0 % over the forecast period 2021-2027. Induced Pluripotent Stem Cells (iPSC) are generated from skin or blood cells that have been reprogrammed into an embryonic-like pluripotent state, allowing to produce an infinite source of any kind of human cell required for therapeutic reasons. Implementation of iPSCs in drug industry serves as driver for the market. On the other hand, high application of iPSCs in treating different diseases and injuries serves as another driver for the market. Demand for iPSCs is increasing due to rising requirement for reproducible large-scale stem cell and differentiated progeny production, with minimum variation. In February 2021, Evotec collaborated with the Medical Center Hamburg-Eppendorf. The collaboration focuses on developing iPSC- based cell therapy for the cure of heart failure. Axol Biosciences and Censo Biotechnology agreed to combine in March 2021. This company is on track to become one of the top producers of goods and services in the drug development and screening industry for iPSC-based immune cell, brain, and cardiac modelling. However, aspects such as high cost that comes along with the reprograming of cells and long processes impedes the growth of the market over the forecast period of 2021-2027. Also, favorable government efforts, significant R&D spending, advanced research facilities and trained personnel, and policies relating to cell treatments are likely to increase the market growth during the forecast period.

The regional analysis of global Induced Pluripotent Stem Cells Production Market is considered for the key regions such as Asia Pacific, North America, Europe, Latin America and Rest of the World. North America is the leading region across the world in terms of market share owing to increasing insights into the iPSC platform along with high throughput analysis for drug toxicity. Whereas Asia-Pacific is also anticipated to exhibit highest growth rate over the forecast period 2021-2027. Factors such as increasing R&D projects across countries like Australia, Japan and Singapore would create lucrative growth prospects for the Induced Pluripotent Stem Cells Production Market across Asia-Pacific region.

Major market player included in this report are:
Lonza
Axol Bioscience Ltd.
Evotec
Hitachi Ltd.
Merck KGaA
REPROCELL Inc.
Fate Therapeutics
Thermo Fisher Scientific, Inc.
StemCellFactory III
Applied StemCell Inc.


The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:
By Derived Cell Type:
Hepatocytes
Fibroblasts
Keratinocytes
Amniotic Cells
Others

By Application:
Academic Research
Drug Development And Discovery
Toxicity Screening
Regenerative Medicine

By End-User
Hospitals
Research Laboratories


By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of the World

Furthermore, years considered for the study are as follows:

Historical year - 2018, 2019
Base year - 2020
Forecast period - 2021 to 2027

Target Audience of the Global Induced Pluripotent Stem Cells Production Market in Market Study:

Key Consulting Companies & Advisors
Large, medium-sized, and small enterprises
Venture capitalists
Value-Added Resellers (VARs)
Third-party knowledge providers
Investment bankers
Investors